Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Ewald

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
JAMA Network Open|March 2, 2021
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer DrugsAmanda Katherina Herbrand, Andreas M Schmitt, Matthias Briel, et al.
JAMA Network Open|June 8, 2019
Association of Communication Interventions to Discuss Code Status With Patient Decisions for Do-Not-Resuscitate Orders: A Systematic Review and Meta-analysisChristoph Becker, Leopold Lecheler, Seraina Hochstrasser, et al.
ESMO Open|December 6, 2019
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU projectAmanda Katherina Herbrand, Andreas Michael Schmitt, Matthias Briel, et al.
The Cochrane Database of Systematic Reviews|September 23, 2024
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Hannah Ewald, Esra Bilir, et al.
Journal of Clinical Epidemiology|August 12, 2020
Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: a meta-epidemiological studyHannah Ewald, Irma Klerings, Gernot Wagner, et al.
Trials|September 21, 2018
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugsAviv Ladanie, Benjamin Speich, Florian Naudet, et al.
Orphanet Journal of Rare Diseases|September 18, 2020
Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)Kimmo Weisshaar, Hannah Ewald, Jörg Halter, et al.
Journal of Clinical Epidemiology|May 28, 2019
A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analysesStefan Schandelmaier, Yaping Chang, Niveditha Devasenapathy, et al.
JAMA Network Open|November 10, 2020
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016Aviv Ladanie, Andreas M Schmitt, Benjamin Speich, et al.
Journal of Clinical Epidemiology|May 8, 2020
Erratum to "A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses" [J Clin Epidemiol. 2019;113:159-67]Stefan Schandelmaier, Yaping Chang, Malgorzata M Bala, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
JAMA Network Open|March 2, 2021
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer DrugsAmanda Katherina Herbrand, Andreas M Schmitt, Matthias Briel, et al.
JAMA Network Open|June 8, 2019
Association of Communication Interventions to Discuss Code Status With Patient Decisions for Do-Not-Resuscitate Orders: A Systematic Review and Meta-analysisChristoph Becker, Leopold Lecheler, Seraina Hochstrasser, et al.
ESMO Open|December 6, 2019
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU projectAmanda Katherina Herbrand, Andreas Michael Schmitt, Matthias Briel, et al.
The Cochrane Database of Systematic Reviews|September 23, 2024
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Hannah Ewald, Esra Bilir, et al.
Journal of Clinical Epidemiology|August 12, 2020
Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: a meta-epidemiological studyHannah Ewald, Irma Klerings, Gernot Wagner, et al.
Trials|September 21, 2018
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugsAviv Ladanie, Benjamin Speich, Florian Naudet, et al.
Orphanet Journal of Rare Diseases|September 18, 2020
Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)Kimmo Weisshaar, Hannah Ewald, Jörg Halter, et al.
Journal of Clinical Epidemiology|May 28, 2019
A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analysesStefan Schandelmaier, Yaping Chang, Niveditha Devasenapathy, et al.
JAMA Network Open|November 10, 2020
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016Aviv Ladanie, Andreas M Schmitt, Benjamin Speich, et al.
Journal of Clinical Epidemiology|May 8, 2020
Erratum to "A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses" [J Clin Epidemiol. 2019;113:159-67]Stefan Schandelmaier, Yaping Chang, Malgorzata M Bala, et al.
Pageof 6